Journal of Clinical Oncology
Articles in this Issue
Impact of pre-visit educational videos on clinic efficiency for prostate cancer radiation oncology consultations.
332 Background: In 2023, there were roughly 175,000 radiation oncology consultations for prostate cancer, with the average...
Optimal duration of immune checkpoint inhibitor therapy in genitourinary cancers: A systematic review and meta-analysis of real-world studies.
470 Background: Immune checkpoint inhibitors (ICIs) have transformed the management of genitourinary (GU) malignancies, pr...
Cost effectiveness of eight first-line regimens in metastatic hormone-sensitive prostate cancer (mHSPC) including niraparib + abiraterone acetate/prednisone.
47 Background: An increase in radiographic progression-free survival (PFS) was observed in the AMPLITUDE trial combining a...
Inherited risk for prostate cancer (PCa): Following the natural history of men with increased genetic risk using multiparametric MRI (mpMRI).
315 Background: PCa has substantial inherited predisposition and certain germline variants like BRCA1/...
Response to primary chemoablation with UGN-102 in different EOTRC risk groups.
733 Background: The ENVISION phase 3 study (NCT05243550) treated patients with recurrent low-grade intermediate-risk non-m...
Therapy-resistant subclones as drivers of progression in aggressive variant prostate cancer.
239 Background: Tumor heterogeneity and clonal evolution are key drivers of cancer progression and therapeutic resistance....
Clinical and cost impact of cabazitaxel versus lutetium-177 vipivotide tetraxetan (Lu-PSMA) for patients with metastatic castration-resistant prostate cancer (mCRPC).
41 Background: The TheraP trial compared cabazitaxel to Lu-PSMA in patients with mCRPC who previously received docetaxel....
Real-world efficacy of nivolumab plus cabozantinib in metastatic renal cell carcinoma (mRCC) using the IMDC.
446 Background: Nivolumab plus Cabozantinib is an established first-line standard of care in mRCC after demonstrating sign...
Three-year median follow-up update of BGB-A317-2002-IIT: A phase 2 study of neoadjuvant tislelizumab plus gemcitabine and cisplatin in patients with cT2–T4aN0M0 muscle-invasive bladder cancer.
783 Background: A multicenter phase II trial evaluating neoadjuvant tislelizumab plus gemcitabine/cisplatin for patients w...
Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with genitourinary extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.
152 Background: Delta-like ligand 3 (DLL3) is highly expressed in neuroendocrine carcinomas (NEC), including extrapulmonar...
Quality improvement initiative to increase osteoporosis screening in patients with prostate cancer on long-term androgen deprivation therapy.
51 Background: Long-term androgen deprivation therapy (ADT) for hormone sensitive prostate cancer (HSPC) is associated wit...
A rules-based AI triage system to identify NCCN-indicated genetic testing in prostate cancer: A performance analysis.
54 Background: Somatic and germline testing in prostate cancer can inform overall prognosis, treatment sequencing decision...
Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905: Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible.
638 Background: The phase 3 KEYNOTE-905/EV-303 study (NCT03924895) showed significantly improved EFS, OS, and pCR rate wit...
End-of-life treatment patterns in patients with advanced urothelial carcinoma.
687 Background: Immune checkpoint inhibitors and antibody-drug conjugates have expanded therapeutic options for advanced u...
Real-world comparative outcomes of abiraterone vs enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC): A propensity-matched analysis from the TriNetX Global Health Research Network.
124 Background: Abiraterone acetate (ABI) and enzalutamide (ENZ) have each demonstrated survival benefit in patients with...
Non-cancer causes of death in patients with hormone-sensitive prostate cancer.
55 Background: The overall survival of men with metastatic hormone-sensitive prostate cancer (mHSPC) has been significantl...
Predictors and clinical outcomes of renal tumor upstaging from cT1 to pT3a disease in patients who underwent robot-assisted partial nephrectomy.
558 Background: Robot-assisted partial nephrectomy (RAPN) is the standard treatment of small renal masses, offering favora...
Assessing impact of RDI on outcomes in patients treated with enfortumab vedotin-pembrolizumab combination therapy.
689 Background: Enfortumab vedotin (EV) and pembrolizumab have emerged as first-line combination therapy for locally advan...
Clinical and biomarker characteristics of treatment-emergent neuroendocrine prostate cancer.
87 Background: Treatment-emergent neuroendocrine prostate cancer (tNEPC) arises as a phenotype of metastatic castration-re...
Spatially resolved HER2 and AR expression in prostate cancer and its implications for HER2 as a distinct therapeutic target.
385 Background: Androgen receptor (AR) target genes are re-expressed during androgen deprivation therapy which stimulates...
Inhibiting α2,6-sialylation and its association with nectin-4 stability and macropinocytic uptake in bladder cancer.
792 Background: Enfortumab vedotin (EV), a Nectin-4–directed ADC, improves outcomes in advanced urothelial carcinoma; howe...
Physician perspectives on the implementability of a cardiovascular risk score for prostate cancer: A PRISM-guided evaluation.
57 Background: Cardiovascular disease (CVD) is the leading non-cancer cause of death among men with prostate cancer (PC),...
The impact of neoadjuvant chemotherapy relative dose intensity on pathological complete response and survival in muscle-invasive urothelial cancer: A multicentric retrospective study.
760 Background: The Relative Dose Intensity (RDI) of neoadjuvant chemotherapy (NAC) is known to influence pathological res...
Role of urinary exosomal FAM153C-RPL19 in detection and risk stratification of prostate cancer: A multicentre Chinese cohort study.
374 Background: Serum PSA lacks specificity for prostate cancer (PCa), especially within the 4–10 ng/mL “grey zone,” leadi...
Improving quality of life measures for use in shared decision-making in advanced prostate cancer.
50 Background: In advanced prostate cancer (aPC), understanding patient treatment goals is the cornerstone of shared decis...